Back to top
more

Fresenius Medical Care AG & Co. (FMS)

(Delayed Data from NYSE)

$21.42 USD

21.42
364,210

-0.51 (-2.33%)

Updated May 21, 2024 04:00 PM ET

After-Market: $21.42 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (94 out of 248)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Megan Sanks headshot

NxStage (NXTM) Jumps 28% on $2 Billion Acquisition by FMS

German dialysis provider Fresenius Medical Care (FMS) announced that it will acquire U.S. home dialysis device maker NxStage Medical, Inc. (NXTM) for $2 billion.

    Surmodics (SRDX) Beats Earnings & Revenue Estimates in Q3

    Surmodics (SRDX) received IDE approval from the FDA for its TRANSCEND SurVeil DCB pivotal study in the third quarter. An upbeat guidance raises investor confidence.

      DexCom (DXCM) in Focus: Stock Moves 6.7% Higher

      DexCom, Inc. (DXCM) was a big mover last session, as the company saw its shares rise nearly 7% on the day after the company reported better-than-expected third quarter, 2017 results.

        AmerisourceBergen (ABC) Beats on Q3 Earnings, Revenues Lag

        AmerisourceBergen Corporation (ABC) posted strong numbers in the second quarter on growth in its Consulting Services, MWI Animal Health and World Courier businesses.

          Fresenius Medical (FMS) Q2 Earnings Miss, FY17 View Intact

          Despite margin contraction in the Dialysis and Care Coordination segments, Fresenius Medical Care (FMS) posted a strong second quarter on solid growth in Asia Pacific and Latin America.

            Masimo (MASI) Beats on Q2 Earnings and Revenues, Guides Up

            Masimo's (MASI) stable performance across its businesses was the key highlight of second quarter.

              Quality Systems (QSII) Beats on Q1 Earnings, Revenues

              Quality Systems (QSII) recorded stellar growth in its recurring revenue base in the first quarter. However, a downbeat guidance for adjusted earnings indicates looming concerns.

                Cardinal Health (CAH) Q4 Earnings Beat Estimates, Rise Y/Y

                Despite registering strong growth at all the segments, unfavorable performances by Cardinal Health's (CAH) Branded products (including Cordis) offset sales, particularly at the Medical segment.

                  DexCom (DXCM) Q2 Loss Narrower Than Expected, Revenues Beat

                  DexCom (DXCM) recorded narrower-than-expected loss in the second quarter owing to robust growth in international space, particularly Germany.

                    Ecolab (ECL) Beats Earnings and Revenue Estimates in Q2

                    Ecolab Inc. (ECL) posted solid numbers in the second quarter owing to new business gains, better pricing, product innovation, and cost efficiencies.

                      Cerner (CERN) Misses Earnings & Revenue Estimates in Q2

                      Despite a stellar bookings growth rate, a downbeat guidance indicates looming concerns for Cerner (CERN). The Support and maintenance segment witnessed a lackluster performance in the second quarter

                        C.R. Bard (BCR) Beats Earnings & Revenue Estimates in Q2

                        C.R. Bard's (BCR) solid performance in the Vascular, Urology and Surgical Specialties were the key highlights of the second quarter.

                          Integer (ITGR) Q2 Earnings Miss, Revenues Beat Estimates

                          Integer's (ITGR) strong performance in the Cardio and Vascular business was a key highlight in second quarter 2017.

                            Abiomed (ABMD) Q1 Earnings and Revenues Beat Estimates

                            Abiomed's (ABMD) strong Impella heart pump performance was a key highlight in first-quarter fiscal 2018.

                              Varian Medical (VAR) Tops Earnings & Lags Revenues in Q3

                              Varian Medical's (VAR) solid performance in the Particle Therapy business and the launch of Halcyon radiotherapy treatment system were the key highlights of the third quarter.

                                Baxter (BAX) Beats on Q2 Earnings, Raises Long-Term Outlook

                                Baxter International (BAX) delivered a solid second quarter driven by favorable tidings on the regulatory front, strategic partnerships and product launches.

                                  Fresenius Medical (FMS) Well Poised on Growth Strategy 2020

                                  On Jul 11, we issued an updated research report on Bad Homburg, Germany-based Fresenius Medical Care (FMS), one of the largest integrated providers of products and services for individuals undergoing dialysis following chronic kidney failure.

                                    Keryx (KERX) Q1 Loss Wider than Expected, Revenues Beat

                                    Keryx Biopharmaceuticals Inc. (KERX) reported first-quarter 2017 loss of 21 cents per share, narrower than the year-ago loss of 39 cents

                                      Fresenius (FMS) Acquires 70% Stake in Kunming Wuhua Hospital

                                      Fresenius Medical Care AG & Co. KGAA announced the acquisition of 70% equity interest in Kunming Wuhua Health Hospital in China.

                                        Fresenius (FMS) to Jointly Develop Acumen with Epic Systems

                                        Fresenius Medical Care AG & Co. KGAA (FMS) announced that it would jointly develop Acumen 2.0 with Epic Systems Corporation.

                                          Keryx Focuses on Kidney Drug Aurexia Despite Generic Threat

                                          We issued an updated research report on Keryx Biopharmaceuticals, Inc. (KERX) on Mar 15, 2017.

                                            Fresenius Medical (FMS) Tops Earnings in Q4, View Upbeat

                                            Fresenius Medical Care AG & Co. KGAA (FMS) reported adjusted earnings of 63 cents per American Depositary Share (ADS) in the fourth quarter of 2016, beating the Zacks Consensus Estimate of 61 cents.